Method of treating skin inflammation

• US 8,178,095 B2
• Filed: 06/17/2010
• Issued: 05/15/2012
• Est. Priority Date: 05/03/2004
• Status: Active Grant

• Current Assignee: Merck Sharp & Dohme LLC (Merck & Co., Inc.)
• Original Assignee: Schering Corporation (Merck & Co., Inc.)
• Inventors: Kastelein, Robert A., McClanahan, Terrill K., Murphy, Erin, Chan, Jason R.
• Primary Examiner(s): Woodward, Cherie M
• Application Number:
  US12/817,432
• Publication Number:
  US 20100254991A1
• Time in Patent Office: 698 Days
• Field of Search: None
• US Class Current: 424/136.1
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.

Claims

1. A method of treating skin inflammation comprising administering to a human subject exhibiting skin inflammation a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that specifically binds to antagonist of at least two cytokines selected from the group consisting of IL-17, IL-19, and IL-23, thereby treating the skin inflammation.

2. The method of claim 1, wherein the skin inflammation is cutaneous inflammation.

3. The method of claim 1, wherein the cutaneous inflammation is psoriasis.

4. The method of claim 1, wherein the subject expresses an average value of at least 5 fold higher IL-17 expression in a non-lesional psoriatic skin sample compared to a normal skin sample, as quantified by real-time PCR.

5. The method of claim 1, wherein the subject expresses an average value of at least 20 fold higher IL-19 expression in a non-lesional psoriatic skin sample compared to a normal skin sample as quantified by real-time PCR.

6. The method of claim 1, wherein the antibody, or antigen-binding fragment thereof, specifically binds to IL-17 and IL-19.

7. The method of claim 6, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-19 is a monoclonal antibody or antigen-binding fragment thereof.

8. The method of claim 6, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-19 is a humanized antibody or antigen-binding fragment thereof.

9. The method of claim 6, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-19 is a bispecific antibody or antigen-binding fragment thereof.

10. The method of claim 1, wherein the antibody, or antigen-binding fragment thereof, specifically binds to IL-17 and IL-23.

11. The method of claim 10, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-23 is a monoclonal antibody or antigen-binding fragment thereof.

12. The method of claim 11, wherein the antibody, or antigen-binding fragment thereof, is a monoclonal antibody.

13. The method of claim 10, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-23 is a humanized antibody or antigen-binding fragment thereof.

14. The method of claim 13, wherein the antibody, or antigen-binding fragment thereof, is a humanized antibody.

15. The method of claim 10, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-23 is a bispecific antibody or antigen-binding fragment thereof.

16. The method of claim 15, wherein the antibody, or antigen-binding fragment thereof, is a bispecific antibody.

17. The method of claim 1, wherein the antibody, or antigen-binding fragment thereof, specifically binds to IL-19 and IL-23.

18. The method of claim 17, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-19 and IL-23 is a monoclonal antibody or antigen-binding fragment thereof.

19. The method of claim 17, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-19 and IL-23 is a humanized antibody or antigen-binding fragment thereof.

20. The method of claim 17, wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-19 and IL-23 is a bispecific antibody or antigen-binding fragment thereof.